Lakeisha Todd
Family · Pleasant View, TNNPI 1881457729
Payments from drug & device makers
Across 80 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$438
- Pfizer$201
- AstraZeneca$194
- AbbVie$130
- Astellas Pharma US Inc$91
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87
- plus $502 from 16 others
What the payments were for
- Food & beverage$1,643100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $438 |
| Pfizer | 11 | $201 |
| AstraZeneca | 11 | $194 |
| AbbVie | 6 | $130 |
| Astellas Pharma US Inc | 4 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $87 |
| Abbott | 3 | $70 |
| GSK | 3 | $49 |
| Corcept Therapeutics | 2 | $45 |
| Lilly USA, LLC | 2 | $37 |
| Bayer | 2 | $33 |
| Dexcom, Inc. | 1 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Novartis | 1 | $30 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $29 |
| Sanofi | 1 | $27 |
| Johnson & Johnson | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Exact Sciences | 1 | $15 |
How this compares
$1,643 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $38,597 |
| XareltoRivaroxaban | 19 | $22,057 |
| EliquisApixaban | 11 | $19,244 |
| JardianceEmpagliflozin | 12 | $11,032 |
| FarxigaDapagliflozin Propanediol | 12 | $10,980 |
| JanuviaSitagliptin Phosphate | 11 | $6,325 |
| Atorvastatin Calcium | 198 | $2,822 |
| Donepezil Hcl | 38 | $1,533 |
| Methylprednisolone | 189 | $1,471 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,462 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 100 | $1,143 |
| Omeprazole | 76 | $1,031 |
| Losartan Potassium | 79 | $916 |
| Bupropion XlBupropion Hcl | 19 | $873 |
| Duloxetine Hcl | 29 | $844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $438 | $38,59729 claims |
| Johnson & JohnsonXarelto | $24 | $22,05719 claims |
| PfizerEliquis | $201 | $19,24411 claims |
| Boehringer IngelheimJardiance | $22 | $11,03212 claims |
| AstraZenecaFarxiga | $194 | $10,98012 claims |
| AbbVieSynthroid | $130 | $45211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.
Other family in Pleasant View
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.